Our site is slower due to heavy traffic from automated ’bots’ and AI crawlers. We’re working to fix this. Read more here.

Tanya Ivanova Stoyanova

Title(s)Department Vice Chair, Molecular and Medical Pharmacology
SchoolMedicine
vCardDownload vCard
    Other Positions
    Title(s)Associate Professor, Molecular and Medical Pharmacology

    Title(s)Associate Professor, Urology


    Collapse Biography 
    Collapse education and training
    University of California, Los Angeles, Los Angeles, CA, USAPostdoctoral Fellowship2015Cancer Biology
    University of Illinois, Chicago, Chicago, IL USAPhD2009Biochemistry and Molecular Genetics
    University of Kansas, Lawrence, KS, USAB.S.2003Biology/Genetics
    Technical University of Varna, Varna, BulgariaB.S.2001Ecology and Protection of the Environment
    Collapse awards and honors
    University of California, Los Angeles2025  - 2026Jonsson Comprehensive Cancer Center and the Broad Stem Cell Research Center Ablon Scholars Award
    Neuroendocrine Tumor Research Foundation2025Neuroendocrine Tumor Research Foundation Pilot Award
    US Department of Defense2024  - 2026Exploration-Hypothesis Development Award, Prostate Cancer Research Program
    US Department of Defense2023  - 2025Idea Development Award, Lung Cancer Research Program
    National Institutes of Health/National Cancer Institute2020  - 2025NIH/NCI R37 MERIT Award
    Society of Basic Urologic Research2020Young Investigator Award
    US Department of Defense2018  - 2020Idea Development Award, Prostate Cancer Research Program
    Stanford University 2016  - 2018Stanford University School of Medicine McCormick and Gabilan Faculty Award
    National Institutes of Health/National Cancer Institute2014  - 2019K99/R00 Pathway to Independence Award
    Prostate Cancer Foundation2014  - 2017Stewart Rahr Prostate Cancer Foundation Young Investigator Award
    University of California, Los Angeles2014Chancellor's Award for Postdoctoral Research
    University of California, Los Angeles2014Department of Molecular and Medical Pharmacology Retreat Award
    US Department of Defense2012  - 2014Postdoctoral Fellowship
    California Institute for Regenerative Medicine2010  - 2012Postdoctoral Fellowship
    University of Illinois, Chicago2008SIGMA Xi Student Research Forum Award for Graduate and Professional Students
    University of Illinois, Chicago2007SIGMA Xi Student Research Forum Award for Graduate and Professional Students
    University of Kansas2003Sally Frost Mason Outstanding Woman Student in Biological Sciences
    University of Kansas2001  - 2002Ruben Zadigan Environmental Studies Scholarship
    University of Kansas2003Sally K. Frost Mason and Kenneth A. Mason Outstanding Senior, Division of Biological Sciences

    Collapse Overview 
    Collapse overview
    Stoyanova lab develops new cancer early detection approaches and therapeutic strategies for late stage cancers. The current research areas of interest are:

    1) Targeted cancer therapies. Stoyanova lab utilizes multiple approaches to develop new therapeutic strategies for late-stage cancers, including discovery and testing new therapeutic targets and new small molecule inhibitors.

    2) Antibody-based therapies for advanced prostate and other metastatic epithelial cancers. Stoyanova lab develops and tests antibody-based strategies as targeted cancer therapies.

    3) Combination therapies for metastatic cancers. We are testing multiple experimental agents in combination with FDA-approved cancer therapies to enhance therapeutic responses.

    4) Protein-based biomarkers for cancer early detection. We are interested in the discovery and development of new tissue, blood, and urine-based biomarkers for significant prostate cancer and other epithelial cancers.

    5) Imaging modalities for cancer. The lab is interested in developing new positron emission tomography (PET) imaging modalities for epithelial cancers to improve cancer early detection and monitor treatment responses.

    The ultimate goals of the laboratory are to improve the early diagnosis and prognosis of clinically significant cancers and guide the development of novel and effective therapeutic strategies for metastatic cancers.

    Collapse Research 
    Collapse research activities and funding
    Testing ATAD2 as a new therapeutic target for advanced prostate cancer
    NIH R01CA287669Jul 1, 2024 - Jun 30, 2029
    Role: Principal Investigator
    UCHL1 is a Novel Minimally Invasive Molecular Indicator and Therapeutic Target for Small Cell Lung Cancer
    US Department of Defense Lung Cancer Research Program HT9425-23-1-1034Sep 15, 2023 - Sep 15, 2025
    Role: Principal Investigator
    Delineate the Role of GSTP1 in Advanced Prostate Cancer
    NIH R01CA274978Jul 14, 2023 - May 31, 2028
    Role: Principal Investigator
    Elucidating the Role of UCHL1 in Aggressive Prostate Cancer
    NIH R01CA244281Jun 15, 2020 - May 31, 2025
    Role: Principal Investigator
    Elucidating the Role of Trop2 in Prostate Cancer
    NIH R37CA240822Apr 1, 2020 - Mar 31, 2025
    Role: Principal Investigator
    Elucidating Novel Mechanisms Underlying Prostate Cancer Development
    NIH R03CA230819Aug 8, 2018 - Jul 31, 2020
    Role: Principal Investigator
    Trop2 as a Novel Driver and Therapeutic Target for Castration-Resistant Prostate Cancer
    US Department of Defense Prostate Cancer Research Program Idea Development Award W81XWH1810323Jan 9, 2018 - Apr 1, 2020
    Role: Principal Investigator
    Proteolytically Cleaved Receptors as Oncogenes and Therapeutic Targets
    NIH R00CA184397Dec 1, 2015 - Nov 30, 2018
    Role: Principal Investigator
    Proteolytically Cleaved Receptors as Oncogenes and Therapeutic Targets
    NIH K99CA184397Sep 1, 2014 - Aug 31, 2016
    Role: Principal Investigator
    The Role of Notch Receptors in Advanced Castration Resistant Prostate Cancer
    Prostate Cancer Foundation Young Investigator Award Mar 1, 2014 - Feb 28, 2018
    Role: Principal Investigator
    The Role of Trop2 Cleavage Products in Prostate Tumorigenesis
    US Department of Defense Prostate Cancer Research Program W81XWM-11-PCRP-PTAJul 1, 2012 - Jun 30, 2014
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Extracellular Vesicles in Serum Carry Trop2 Protein as a Potential Molecular Indicator in Prostate Cancer. J Extracell Biol. 2025 Sep; 4(9):e70083. Sinawang PD, Ozen MO, Liu S, Hsu EC, Akin D, Ding E, Nolley R, Brooks JD, Stoyanova T, Demirci U. PMID: 40994721; PMCID: PMC12456249.
      View in: PubMed   Mentions:
    2. Extracellular Domain Shedding of TROP2 Activates EGFR Signaling to Drive Prostate Cancer Metastasis. Cancer Res. 2025 Sep 05. Liu S, Hsu EC, Aslan M, Garcia-Marques F, Shen M, Hartono AB, Solano F, Le K, Hwang H, Lee CS, Bermudez A, Nolley R, Peehl DM, Brooks JD, Liss MA, Pitteri SJ, Stoyanova T. PMID: 40911783.
      View in: PubMed   Mentions:    Fields:    
    3. Ubiquitin C-terminal hydrolase L1 is a regulator of tumor growth and metastasis in double-negative prostate cancer. Am J Clin Exp Urol. 2024; 12(5):306-322. Liu S, Garcia-Marques FJ, Shen M, Bermudez A, Pitteri SJ, Stoyanova T. PMID: 39584005; PMCID: PMC11578776.
      View in: PubMed   Mentions:
    4. Identification of a 5-gene signature panel for the prediction of prostate cancer progression. Br J Cancer. 2024 Dec; 131(11):1748-1761. Shen M, García-Marqués F, Muruganantham A, Liu S, White JR, Bermudez A, Rice MA, Thompson K, Chen CL, Hung CN, Zhang Z, Huang TH, Liss MA, Pienta KJ, Pitteri SJ, Stoyanova T. PMID: 39402324; PMCID: PMC11589118.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    5. Protocol for establishing spontaneous metastasis in mice using a subcutaneous tumor model. STAR Protoc. 2024 09 20; 5(3):103239. Liu S, Shen M, Le K, Hartono AB, Stoyanova T. PMID: 39096496; PMCID: PMC11342759.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    6. Co-axial hydrogel spinning for facile biofabrication of prostate cancer-like 3D models. Biofabrication. 2024 02 20; 16(2). Guimarães CF, Liu S, Wang J, Purcell E, Ozedirne T, Ren T, Aslan M, Yin Q, Reis RL, Stoyanova T, Demirci U. PMID: 38306674.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    7. UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas. Cell Rep Med. 2024 Feb 20; 5(2):101381. Liu S, Chai T, Garcia-Marques F, Yin Q, Hsu EC, Shen M, Shaw Toland AM, Bermudez A, Hartono AB, Massey CF, Lee CS, Zheng L, Baron M, Denning CJ, Aslan M, Nguyen HM, Nolley R, Zoubeidi A, Das M, Kunder CA, Howitt BE, Soh HT, Weissman IL, Liss MA, Chin AI, Brooks JD, Corey E, Pitteri SJ, Huang J, Stoyanova T. PMID: 38244540; PMCID: PMC10897521.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    8. High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarker. Sci Rep. 2024 01 04; 14(1):486. Liu S, Hawley SJ, Kunder CA, Hsu EC, Shen M, Westphalen L, Auman H, Newcomb LF, Lin DW, Nelson PS, Feng Z, Tretiakova MS, True LD, Vakar-Lopez F, Carroll PR, Simko J, Gleave ME, Troyer DA, McKenney JK, Brooks JD, Liss MA, Stoyanova T. PMID: 38177207; PMCID: PMC10766957.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    9. Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategy. Proc Natl Acad Sci U S A. 2023 Nov 21; 120(47):e2312374120. Bangayan NJ, Wang L, Burton Sojo G, Noguchi M, Cheng D, Ta L, Gunn D, Mao Z, Liu S, Yin Q, Riedinger M, Li K, Wu AM, Stoyanova T, Witte ON. PMID: 37963244; PMCID: PMC10666036.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    10. ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotype. Br J Cancer. 2023 11; 129(11):1818-1828. Shen M, Liu S, Toland A, Hsu EC, Hartono AB, Alabi BR, Aslan M, Nguyen HM, Sessions CJ, Nolley R, Shi C, Huang J, Brooks JD, Corey E, Stoyanova T. PMID: 37798372; PMCID: PMC10667239.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    11. Proteomics analysis of urine and catheter-associated biofilms in spinal cord injury patients. Am J Clin Exp Urol. 2023; 11(3):206-219. Garcia-Marques FJ, Zakrasek E, Bermudez A, Polasko AL, Liu S, Stoyanova T, Brooks JD, Lavelle J, Pitteri SJ. PMID: 37441441; PMCID: PMC10333135.
      View in: PubMed   Mentions:
    12. Multimodal In Vivo Tracking of Chimeric Antigen Receptor T Cells in Preclinical Glioblastoma Models. Invest Radiol. 2023 06 01; 58(6):388-395. Wu WE, Chang E, Jin L, Liu S, Huang CH, Kamal R, Liang T, Aissaoui NM, Theruvath AJ, Pisani L, Moseley M, Stoyanova T, Paulmurugan R, Huang J, Mitchell DA, Daldrup-Link HE. PMID: 36729074; PMCID: PMC10164035.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    13. Current and emerging therapies for neuroendocrine prostate cancer. Pharmacol Ther. 2022 10; 238:108255. Alabi BR, Liu S, Stoyanova T. PMID: 35905791.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    14. Volbots: Volvox Microalgae-Based Robots for Multimode Precision Imaging and Therapy. Advanced Functional Materials. 2022. Wang J, Soto F, Liu S, Zeng Y, Hsu EC, Akin D, Sinclair B, Stoyanova T, Demirci U. View Publication.
    15. Acoustic Fabrication of Living Cardiomyocyte-based Hybrid Biorobots. ACS Nano. 2022 07 26; 16(7):10219-10230. Wang J, Soto F, Ma P, Ahmed R, Yang H, Chen S, Wang J, Liu C, Akin D, Fu K, Cao X, Chen P, Hsu EC, Soh HT, Stoyanova T, Wu JC, Demirci U. PMID: 35671037.
      View in: PubMed   Mentions: 6     Fields:    Translation:Cells
    16. Molecular mechanisms underlying the development of neuroendocrine prostate cancer. Semin Cancer Biol. 2022 11; 86(Pt 3):57-68. Liu S, Alabi BR, Yin Q, Stoyanova T. PMID: 35597438.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    17. Correlation of 68Ga-RM2 PET with Postsurgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer. J Nucl Med. 2022 12; 63(12):1829-1835. Duan H, Baratto L, Fan RE, Soerensen SJC, Liang T, Chung BI, Thong AEC, Gill H, Kunder C, Stoyanova T, Rusu M, Loening AM, Ghanouni P, Davidzon GA, Moradi F, Sonn GA, Iagaru A. PMID: 35552245; PMCID: PMC12360193.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    18. SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer. Cell Rep Med. 2022 02 15; 3(2):100502. Rice MA, Kumar V, Tailor D, Garcia-Marques FJ, Hsu EC, Liu S, Bermudez A, Kanchustambham V, Shankar V, Inde Z, Alabi BR, Muruganantham A, Shen M, Pandrala M, Nolley R, Aslan M, Ghoochani A, Agarwal A, Buckup M, Kumar M, Going CC, Peehl DM, Dixon SJ, Zare RN, Brooks JD, Pitteri SJ, Malhotra SV, Stoyanova T. PMID: 35243415; PMCID: PMC8861828.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    19. Protein signatures to distinguish aggressive from indolent prostate cancer. Prostate. 2022 04; 82(5):605-616. Garcia-Marques F, Liu S, Totten SM, Bermudez A, Tanimoto C, Hsu EC, Nolley R, Hembree A, Stoyanova T, Brooks JD, Pitteri SJ. PMID: 35098564; PMCID: PMC8916040.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    20. Metastasis Model to Test the Role of Notch Signaling in Prostate Cancer. Methods Mol Biol. 2022; 2472:221-233. Liu S, Hsu EC, Shen M, Aslan M, Stoyanova T. PMID: 35674904.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    21. Oncogene-mediated metabolic gene signature predicts breast cancer outcome. NPJ Breast Cancer. 2021 Oct 28; 7(1):141. Aslan M, Hsu EC, Garcia-Marques FJ, Bermudez A, Liu S, Shen M, West M, Zhang CA, Rice MA, Brooks JD, West R, Pitteri SJ, Gyorffy B, Stoyanova T. PMID: 34711841; PMCID: PMC8553750.
      View in: PubMed   Mentions: 28  
    22. Engineering Polysaccharide-Based Hydrogel Photonic Constructs: From Multiscale Detection to the Biofabrication of Living Optical Fibers. Adv Mater. 2021 Dec; 33(52):e2105361. Guimarães CF, Ahmed R, Mataji-Kojouri A, Soto F, Wang J, Liu S, Stoyanova T, Marques AP, Reis RL, Demirci U. PMID: 34617338.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    23. Quantifying the invasion and migration ability of cancer cells with a 3D Matrigel drop invasion assay. Biol Methods Protoc. 2021; 6(1):bpab014. Aslan M, Hsu EC, Liu S, Stoyanova T. PMID: 34377838; PMCID: PMC8346651.
      View in: PubMed   Mentions: 18  
    24. MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer. Sci Rep. 2021 06 25; 11(1):13305. Hsu EC, Shen M, Aslan M, Liu S, Kumar M, Garcia-Marques F, Nguyen HM, Nolley R, Pitteri SJ, Corey E, Brooks JD, Stoyanova T. PMID: 34172788; PMCID: PMC8233352.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    25. Increasing Diversity in Radiology and Molecular Imaging: Current Challenges. Mol Imaging Biol. 2021 10; 23(5):625-638. Fite BZ, Hinostroza V, States L, Hicks-Nelson A, Baratto L, Kallianos K, Codari M, Yu B, Jha P, Shams M, Stoyanova T, Chapelin FF, Liu A, Rashidi A, Soto F, Quintana Y, Davidzon GA, Marycz K, Gibbs IC, Chonde DB, Patel CB, Daldrup-Link HE. PMID: 33903986; PMCID: PMC8074707.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    26. Discovery of CASP8 as a potential biomarker for high-risk prostate cancer through a high-multiplex immunoassay. Sci Rep. 2021 04 07; 11(1):7612. Liu S, Garcia-Marques F, Zhang CA, Lee JJ, Nolley R, Shen M, Hsu EC, Aslan M, Koul K, Pitteri SJ, Brooks JD, Stoyanova T. PMID: 33828176; PMCID: PMC8027881.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    27. Ultra-high-frequency radio-frequency acoustic molecular imaging with saline nanodroplets in living subjects. Nat Nanotechnol. 2021 06; 16(6):717-724. Chen YS, Zhao Y, Beinat C, Zlitni A, Hsu EC, Chen DH, Achterberg F, Wang H, Stoyanova T, Dionne J, Gambhir SS. PMID: 33782588; PMCID: PMC8454903.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    28. In Vivo Imaging of Methionine Aminopeptidase II for Prostate Cancer Risk Stratification. Cancer Res. 2021 05 01; 81(9):2510-2521. Xie J, Rice MA, Chen Z, Cheng Y, Hsu EC, Chen M, Song G, Cui L, Zhou K, Castillo JB, Zhang CA, Shen B, Chin FT, Kunder CA, Brooks JD, Stoyanova T, Rao J. PMID: 33637565; PMCID: PMC8137584.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    29. The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target. Am J Clin Exp Urol. 2021; 9(1):73-87. Shen M, Liu S, Stoyanova T. PMID: 33816696; PMCID: PMC8012837.
      View in: PubMed   Mentions: 25  
    30. Ferroptosis Inducers Are a Novel Therapeutic Approach for Advanced Prostate Cancer. Cancer Res. 2021 03 15; 81(6):1583-1594. Ghoochani A, Hsu EC, Aslan M, Rice MA, Nguyen HM, Brooks JD, Corey E, Paulmurugan R, Stoyanova T. PMID: 33483372; PMCID: PMC7969452.
      View in: PubMed   Mentions: 153     Fields:    Translation:HumansAnimalsCells
    31. Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer. Br J Cancer. 2021 03; 124(5):896-900. Liu S, Shen M, Hsu EC, Zhang CA, Garcia-Marques F, Nolley R, Koul K, Rice MA, Aslan M, Pitteri SJ, Massie C, George A, Brooks JD, Gnanapragasam VJ, Stoyanova T. PMID: 33288843; PMCID: PMC7921397.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    32. Plectin is a regulator of prostate cancer growth and metastasis. Oncogene. 2021 01; 40(3):663-676. Buckup M, Rice MA, Hsu EC, Garcia-Marques F, Liu S, Aslan M, Bermudez A, Huang J, Pitteri SJ, Stoyanova T. PMID: 33219316; PMCID: PMC8078627.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimalsCells
    33. Novel Aza-podophyllotoxin derivative induces oxidative phosphorylation and cell death via AMPK activation in triple-negative breast cancer. Br J Cancer. 2021 02; 124(3):604-615. Tailor D, Going CC, Resendez A, Kumar V, Nambiar DK, Li Y, Dheeraj A, LaGory EL, Ghoochani A, Birk AM, Stoyanova T, Ye J, Giaccia AJ, Le QT, Singh RP, Sledge GW, Pitteri SJ, Malhotra SV. PMID: 33139797; PMCID: PMC7851402.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    34. Gold Nanoclusters for NIR-II Fluorescence Imaging of Bones. Small. 2020 10; 16(43):e2003851. Li D, Liu Q, Qi Q, Shi H, Hsu EC, Chen W, Yuan W, Wu Y, Lin S, Zeng Y, Xiao Z, Xu L, Zhang Y, Stoyanova T, Jia W, Cheng Z. PMID: 33000882.
      View in: PubMed   Mentions: 40     Fields:    
    35. Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1. Proc Natl Acad Sci U S A. 2020 01 28; 117(4):2032-2042. Hsu EC, Rice MA, Bermudez A, Marques FJG, Aslan M, Liu S, Ghoochani A, Zhang CA, Chen YS, Zlitni A, Kumar S, Nolley R, Habte F, Shen M, Koul K, Peehl DM, Zoubeidi A, Gambhir SS, Kunder CA, Pitteri SJ, Brooks JD, Stoyanova T. PMID: 31932422; PMCID: PMC6994991.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansAnimalsCells
    36. Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer. Front Oncol. 2019; 9:801. Rice MA, Malhotra SV, Stoyanova T. PMID: 31555580; PMCID: PMC6723105.
      View in: PubMed   Mentions: 148  
    37. Loss of Notch1 Activity Inhibits Prostate Cancer Growth and Metastasis and Sensitizes Prostate Cancer Cells to Antiandrogen Therapies. Mol Cancer Ther. 2019 07; 18(7):1230-1242. Rice MA, Hsu EC, Aslan M, Ghoochani A, Su A, Stoyanova T. PMID: 31028097; PMCID: PMC7280023.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansAnimalsCells
    38. Biomarkers for Diagnosis and Prognosis of Prostate Cancer. Prostatectomy. 2018. Rice MA, Stoyanova T. .
    39. Quantitative Proteomic Profiling Reveals Key Pathways in the Anticancer Action of Methoxychalcone Derivatives in Triple Negative Breast Cancer. J Proteome Res. 2018 10 05; 17(10):3574-3585. Going CC, Tailor D, Kumar V, Birk AM, Pandrala M, Rice MA, Stoyanova T, Malhotra S, Pitteri SJ. PMID: 30200768; PMCID: PMC8078626.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    40. The Exosome Total Isolation Chip. ACS Nano. 2017 11 28; 11(11):10712-10723. Liu F, Vermesh O, Mani V, Ge TJ, Madsen SJ, Sabour A, Hsu EC, Gowrishankar G, Kanada M, Jokerst JV, Sierra RG, Chang E, Lau K, Sridhar K, Bermudez A, Pitteri SJ, Stoyanova T, Sinclair R, Nair VS, Gambhir SS, Demirci U. PMID: 29090896; PMCID: PMC5983373.
      View in: PubMed   Mentions: 172     Fields:    Translation:HumansCells
    41. Low CD38 Identifies Progenitor-like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome. Cell Rep. 2016 12 06; 17(10):2596-2606. Liu X, Grogan TR, Hieronymus H, Hashimoto T, Mottahedeh J, Cheng D, Zhang L, Huang K, Stoyanova T, Park JW, Shkhyan RO, Nowroozizadeh B, Rettig MB, Sawyers CL, Elashoff D, Horvath S, Huang J, Witte ON, Goldstein AS. PMID: 27926864; PMCID: PMC5367888.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansCells
    42. Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2016 10 18; 113(42):E6457-E6466. Stoyanova T, Riedinger M, Lin S, Faltermeier CM, Smith BA, Zhang KX, Going CC, Goldstein AS, Lee JK, Drake JM, Rice MA, Hsu EC, Nowroozizadeh B, Castor B, Orellana SY, Blum SM, Cheng D, Pienta KJ, Reiter RE, Pitteri SJ, Huang J, Witte ON. PMID: 27694579; PMCID: PMC5081658.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimalsCells
    43. v-Src Oncogene Induces Trop2 Proteolytic Activation via Cyclin D1. Cancer Res. 2016 11 15; 76(22):6723-6734. Ju X, Jiao X, Ertel A, Casimiro MC, Di Sante G, Deng S, Li Z, Di Rocco A, Zhan T, Hawkins A, Stoyanova T, Andò S, Fatatis A, Lisanti MP, Gomella LG, Languino LR, Pestell RG. PMID: 27634768; PMCID: PMC5330252.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    44. Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer. Cell. 2016 Aug 11; 166(4):1041-1054. Drake JM, Paull EO, Graham NA, Lee JK, Smith BA, Titz B, Stoyanova T, Faltermeier CM, Uzunangelov V, Carlin DE, Fleming DT, Wong CK, Newton Y, Sudha S, Vashisht AA, Huang J, Wohlschlegel JA, Graeber TG, Witte ON, Stuart JM. PMID: 27499020; PMCID: PMC4985183.
      View in: PubMed   Mentions: 127     Fields:    Translation:HumansCells
    45. N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. Cancer Cell. 2016 Apr 11; 29(4):536-547. Lee JK, Phillips JW, Smith BA, Park JW, Stoyanova T, McCaffrey EF, Baertsch R, Sokolov A, Meyerowitz JG, Mathis C, Cheng D, Stuart JM, Shokat KM, Gustafson WC, Huang J, Witte ON. PMID: 27050099; PMCID: PMC4829466.
      View in: PubMed   Mentions: 261     Fields:    Translation:HumansAnimalsCells
    46. Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting. Prostate. 2016 Feb; 76(2):125-39. Miyahira AK, Lang JM, Den RB, Garraway IP, Lotan TL, Ross AE, Stoyanova T, Cho SY, Simons JW, Pienta KJ, Soule HR. PMID: 26477609; PMCID: PMC5830186.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    47. Distinct phases of human prostate cancer initiation and progression can be driven by different cell-types. Cancer Cell Microenviron. 2014; 1(3). Stoyanova T, Goldstein AS. PMID: 26005704; PMCID: PMC4441270.
      View in: PubMed   Mentions: 2  
    48. Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells. Proc Natl Acad Sci U S A. 2013 Dec 10; 110(50):20111-6. Stoyanova T, Cooper AR, Drake JM, Liu X, Armstrong AJ, Pienta KJ, Zhang H, Kohn DB, Huang J, Witte ON, Goldstein AS. PMID: 24282295; PMCID: PMC3864278.
      View in: PubMed   Mentions: 110     Fields:    Translation:HumansCells
    49. Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. Proc Natl Acad Sci U S A. 2013 Dec 03; 110(49):E4762-9. Drake JM, Graham NA, Lee JK, Stoyanova T, Faltermeier CM, Sud S, Titz B, Huang J, Pienta KJ, Graeber TG, Witte ON. PMID: 24248375; PMCID: PMC3856845.
      View in: PubMed   Mentions: 73     Fields:    Translation:HumansCells
    50. Identification, characterization and targeting of Docetaxel-resistant prostate cancer cells. Asian J Androl. 2013 Jan; 15(1):83-4. Stoyanova TI, Goldstein AS. PMID: 23202701; PMCID: PMC3739119.
      View in: PubMed   Mentions:    Fields:    
    51. Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via β-catenin signaling. Genes Dev. 2012 Oct 15; 26(20):2271-85. Stoyanova T, Goldstein AS, Cai H, Drake JM, Huang J, Witte ON. PMID: 23070813; PMCID: PMC3475800.
      View in: PubMed   Mentions: 93     Fields:    Translation:HumansAnimalsCells
    52. Collaboration of Kras and androgen receptor signaling stimulates EZH2 expression and tumor-propagating cells in prostate cancer. Cancer Res. 2012 Sep 15; 72(18):4672-81. Cai H, Memarzadeh S, Stoyanova T, Beharry Z, Kraft AS, Witte ON. PMID: 22805308; PMCID: PMC3445707.
      View in: PubMed   Mentions: 28     Fields:    Translation:AnimalsCells
    53. Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression. Proc Natl Acad Sci U S A. 2012 Jan 31; 109(5):1643-8. Drake JM, Graham NA, Stoyanova T, Sedghi A, Goldstein AS, Cai H, Smith DA, Zhang H, Komisopoulou E, Huang J, Graeber TG, Witte ON. PMID: 22307624; PMCID: PMC3277127.
      View in: PubMed   Mentions: 93     Fields:    Translation:AnimalsCells
    54. p21 cooperates with DDB2 protein in suppression of ultraviolet ray-induced skin malignancies. J Biol Chem. 2012 Jan 27; 287(5):3019-28. Stoyanova T, Roy N, Bhattacharjee S, Kopanja D, Valli T, Bagchi S, Raychaudhuri P. PMID: 22167187; PMCID: PMC3270959.
      View in: PubMed   Mentions: 24     Fields:    Translation:AnimalsCells
    55. Cul4A is essential for spermatogenesis and male fertility. Dev Biol. 2011 Apr 15; 352(2):278-87. Kopanja D, Roy N, Stoyanova T, Hess RA, Bagchi S, Raychaudhuri P. PMID: 21291880; PMCID: PMC3065526.
      View in: PubMed   Mentions: 52     Fields:    Translation:AnimalsCells
    56. Primitive origins of prostate cancer: in vivo evidence for prostate-regenerating cells and prostate cancer-initiating cells. Mol Oncol. 2010 Oct; 4(5):385-96. Goldstein AS, Stoyanova T, Witte ON. PMID: 20688584; PMCID: PMC2939195.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCells
    57. DDB2 (damaged-DNA binding protein 2) in nucleotide excision repair and DNA damage response. Cell Cycle. 2009 Dec 15; 8(24):4067-71. Stoyanova T, Roy N, Kopanja D, Raychaudhuri P, Bagchi S. PMID: 19923893; PMCID: PMC3107032.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansAnimalsCells
    58. DDB2 decides cell fate following DNA damage. Proc Natl Acad Sci U S A. 2009 Jun 30; 106(26):10690-5. Stoyanova T, Roy N, Kopanja D, Bagchi S, Raychaudhuri P. PMID: 19541625; PMCID: PMC2705559.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansAnimalsCells
    59. Proliferation defects and genome instability in cells lacking Cul4A. Oncogene. 2009 Jul 02; 28(26):2456-65. Kopanja D, Stoyanova T, Okur MN, Huang E, Bagchi S, Raychaudhuri P. PMID: 19430492; PMCID: PMC2705479.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCells
    60. The xeroderma pigmentosum group E gene product DDB2 activates nucleotide excision repair by regulating the level of p21Waf1/Cip1. Mol Cell Biol. 2008 Jan; 28(1):177-87. Stoyanova T, Yoon T, Kopanja D, Mokyr MB, Raychaudhuri P. PMID: 17967871; PMCID: PMC2223305.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansAnimalsCells
    Tanya's Networks
    Concepts (278)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (22)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-16-gff1bd585 on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California